On Aug. 4, 2020, Precipio announced it had completed the internal validation of the U.S. Food and Drug Administration (FDA)-authorized COVID-19 serology antibody test in its CLIA laboratory, and had launched the test commercially to its pathology customer base (phase 1).

Upon obtaining further approval for expanded use by FDA, phase 2 planned broaden their distribution to POC (point-of-care) healthcare facilities including hospitals, medical centers, urgent care facilities and physician practices.